FDA:GSK的Nucala(美泊利单抗)获批用于治疗慢性鼻窦炎鼻息肉

2021-08-02 Allan MedSci原创

慢性鼻窦炎是指持续时间超过 12 周的副鼻窦炎症。症状包括面部闷胀、流涕、鼻后滴流、鼻塞和全身不适。根据伴和不伴鼻息肉,慢性鼻窦炎分为两大类。

慢性鼻窦炎是指持续时间超过 12 周的副鼻窦炎症。症状包括面部闷胀、流涕、鼻后滴流、鼻塞和全身不适。根据伴和不伴鼻息肉,慢性鼻窦炎分为两大类。

鼻息肉是在鼻子或鼻窦里生长的肉芽肿,大多是未癌化的良性组织(图1)。症状包括呼吸困难、嗅觉丧失、味觉变差、鼻涕倒流以及流鼻涕。一般的鼻息肉外观大多呈现袋状、无痛的突起肉芽。一般而言患者的双侧鼻孔都会同时有鼻息肉。有时候也可能同时发生脸部的疼痛,或是导致鼻窦炎。

pastedGraphic.png

图1.鼻息肉的病理成像

葛兰素史克 (GSK) 的白细胞介素-5 (IL-5) 抑制剂已获得美国食品和药品监督管理局 (FDA) 的批准,用于治疗伴有鼻息肉的慢性鼻窦炎 (CRSwNP)。获批后,Nucala(美泊利单抗)成为美国首个用于CRSwNP成人患者的抗 IL-5 生物制剂。

FDA 已批准 Nucala 作为对鼻用皮质类固醇反应不足的 18 岁及以上成年 CRSwNP 患者的附加维持治疗。该批准基于葛兰素史克 SYNAPSE 研究的数据,该研究评估了 Nucala 与安慰剂对 400 多例 CRSwNP 患者的影响。在这项试验中,Nucala 显著减少鼻息肉和鼻塞的大小。此外,在 SYNAPSE 研究中,与安慰剂组相比,Nucala 治疗组患者接受手术的比例降低了 57%(图2)。在接受 Nucala 治疗的组中,在 52 周治疗期间需要全身性使用皮质类固醇的患者数量也较少。

 

pastedGraphic_1.png

图2.意向治疗人群中进行鼻腔手术患者的比例:安慰剂组 (23%) 和Nucala组 (9%)

葛兰素史克首席科学官兼研发总裁Hal Barron说:“美国有超过 500 万人患有伴有鼻息肉的慢性鼻窦炎,今天的批准为这些患者提供了第一个抗 IL-5 治疗选择和手术替代方案,以帮助减轻这种疾病的症状”。

 

原始出处:

http://www.pharmatimes.com/news/gsks_nucala_approved_to_treat_chronic_rhinosinusitis_with_nasal_polyps_1373848

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1980350, encodeId=4ef91980350eb, content=<a href='/topic/show?id=cb03e99705c' target=_blank style='color:#2F92EE;'>#美泊利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79970, encryptionId=cb03e99705c, topicName=美泊利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed Sep 29 09:04:12 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077089, encodeId=35d820e7089b0, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 21 16:04:12 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351421, encodeId=179e13514219f, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569837, encodeId=4034156983e8a, content=<a href='/topic/show?id=61d913138ba' target=_blank style='color:#2F92EE;'>#Nucala#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13138, encryptionId=61d913138ba, topicName=Nucala)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2e15575729, createdName=tastas, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004558, encodeId=d24b10045580a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Aug 02 09:16:03 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004523, encodeId=6f7f100452353, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Aug 02 07:02:46 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1980350, encodeId=4ef91980350eb, content=<a href='/topic/show?id=cb03e99705c' target=_blank style='color:#2F92EE;'>#美泊利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79970, encryptionId=cb03e99705c, topicName=美泊利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed Sep 29 09:04:12 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077089, encodeId=35d820e7089b0, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 21 16:04:12 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351421, encodeId=179e13514219f, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569837, encodeId=4034156983e8a, content=<a href='/topic/show?id=61d913138ba' target=_blank style='color:#2F92EE;'>#Nucala#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13138, encryptionId=61d913138ba, topicName=Nucala)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2e15575729, createdName=tastas, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004558, encodeId=d24b10045580a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Aug 02 09:16:03 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004523, encodeId=6f7f100452353, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Aug 02 07:02:46 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1980350, encodeId=4ef91980350eb, content=<a href='/topic/show?id=cb03e99705c' target=_blank style='color:#2F92EE;'>#美泊利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79970, encryptionId=cb03e99705c, topicName=美泊利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed Sep 29 09:04:12 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077089, encodeId=35d820e7089b0, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 21 16:04:12 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351421, encodeId=179e13514219f, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569837, encodeId=4034156983e8a, content=<a href='/topic/show?id=61d913138ba' target=_blank style='color:#2F92EE;'>#Nucala#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13138, encryptionId=61d913138ba, topicName=Nucala)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2e15575729, createdName=tastas, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004558, encodeId=d24b10045580a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Aug 02 09:16:03 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004523, encodeId=6f7f100452353, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Aug 02 07:02:46 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1980350, encodeId=4ef91980350eb, content=<a href='/topic/show?id=cb03e99705c' target=_blank style='color:#2F92EE;'>#美泊利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79970, encryptionId=cb03e99705c, topicName=美泊利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed Sep 29 09:04:12 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077089, encodeId=35d820e7089b0, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 21 16:04:12 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351421, encodeId=179e13514219f, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569837, encodeId=4034156983e8a, content=<a href='/topic/show?id=61d913138ba' target=_blank style='color:#2F92EE;'>#Nucala#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13138, encryptionId=61d913138ba, topicName=Nucala)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2e15575729, createdName=tastas, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004558, encodeId=d24b10045580a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Aug 02 09:16:03 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004523, encodeId=6f7f100452353, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Aug 02 07:02:46 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-03 tastas
  5. [GetPortalCommentsPageByObjectIdResponse(id=1980350, encodeId=4ef91980350eb, content=<a href='/topic/show?id=cb03e99705c' target=_blank style='color:#2F92EE;'>#美泊利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79970, encryptionId=cb03e99705c, topicName=美泊利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed Sep 29 09:04:12 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077089, encodeId=35d820e7089b0, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 21 16:04:12 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351421, encodeId=179e13514219f, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569837, encodeId=4034156983e8a, content=<a href='/topic/show?id=61d913138ba' target=_blank style='color:#2F92EE;'>#Nucala#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13138, encryptionId=61d913138ba, topicName=Nucala)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2e15575729, createdName=tastas, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004558, encodeId=d24b10045580a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Aug 02 09:16:03 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004523, encodeId=6f7f100452353, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Aug 02 07:02:46 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-02 1244c0ebm28暂无昵称

    学习学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1980350, encodeId=4ef91980350eb, content=<a href='/topic/show?id=cb03e99705c' target=_blank style='color:#2F92EE;'>#美泊利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79970, encryptionId=cb03e99705c, topicName=美泊利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed Sep 29 09:04:12 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077089, encodeId=35d820e7089b0, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2260, encryptionId=955d226045, topicName=ALA)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 21 16:04:12 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351421, encodeId=179e13514219f, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569837, encodeId=4034156983e8a, content=<a href='/topic/show?id=61d913138ba' target=_blank style='color:#2F92EE;'>#Nucala#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13138, encryptionId=61d913138ba, topicName=Nucala)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a2e15575729, createdName=tastas, createdTime=Tue Aug 03 20:04:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004558, encodeId=d24b10045580a, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Aug 02 09:16:03 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004523, encodeId=6f7f100452353, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Aug 02 07:02:46 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-02 yangchou

    好文章,谢谢分享。

    0

相关资讯

JAMA子刊:FDA为什么会加速批准阿尔茨海默病新药Aducanumab?

这是20年来第一个治疗阿尔茨海默病的新药物。

2021年上半年盘点:FDA批准52款新药,6款生物制品

2021年1月至6月,美国FDA共计批准了52款新药,6款生物制品(CDER批准)。按照企业提交的申请分类包括新分子实体类占比50%,新酯新盐类或其他非共价键的衍生物类5%,新剂型10%,新配方26%

康方生物PD-1获FDA突破性疗法资格,三线治疗转移性鼻咽癌

2020年9月,康方生物宣布派安普利单抗三线治疗转移性鼻咽癌的注册性临床试验达到了由独立影像评估的客观缓解率(ORR)主要终点。

2021年上半年盘点:FDA批准抗肿瘤药物汇总

2021年上半年,FDA批准涉及22种药物的35个适应症(其中加速批准适应症14个)。FDA批准了共22款抗癌新疗法,包括靶向,免疫检查点抑制剂,过继性细胞免疫疗法等等,覆盖了几乎全部的癌症种类,值得

2021 ASCO大会日程预告1(6月4日)

开幕式上,ASCO主席洛里-皮尔斯博士(Lori Pierce)将发表主题演讲,并邀请卫生政策方面的专家作为演讲嘉宾。

FDA批准针对复发性心包炎的疗法

美国FDA已批准Kiniksa Pharmaceuticals开发的IL-1抑制剂Arcalyst(rilonacept)上市,用于治疗12岁以上复发性心包炎(recurrent pericardit

拓展阅读

World Allergy Organ J:现实世界中成年哮喘患者的慢性鼻窦炎诊断生物标志物有哪些?

研究人员开发了生物标志物来预测成年哮喘患者的 CRS。结果发现,periostin、DPP10 和 AERD 表型是预测成人哮喘患者 CRS 的重要生物标志物。

Otolaryngol Head Neck Surg:当不是过敏性鼻炎时,怀疑患者患有慢性鼻窦炎的临床症状有哪些?

研究人员确定了以鼻过敏为主诉的患者患CRS的预测因素。结果表明,认为自己患有过敏性鼻炎的患者出现中度或更严重的鼻塞或流鼻涕症状、嗅觉/味觉减退或鼻内窥镜检查结果呈阳性时,应及时对CRS进行评估。

Int Forum Allergy Rhinol:慢性鼻窦炎伴鼻息肉患者中,炎症生物标志物与疾病控制之间有何关系?

研究人员确定了 IL-5 和 calprotectin 是否有助于确定疾病的严重程度和识别不受控制的患者。结果发现,IL-5可能有助于识别病情较重的患者。

Allergy:颗粒物暴露与慢性鼻窦炎患者炎性细胞因子和嗜酸性粒细胞的增加有关

研究人员推测,PM2.5 可能会导致不同的细胞因子模式。结果发现,长期暴露于PM2.5可能是混合型和2型CRS炎症反应的独立风险因素。

Am J Otolaryngol:成人自身免疫性疾病与慢性鼻窦炎有何关系?

研究人员分析了自身免疫性疾病与鼻窦炎之间的关联。结果发现,自身免疫性疾病与鼻窦炎(包括 CRS 和 RARS)有关,而与其他风险因素无关。

Int Forum Allergy Rhinol:伴有鼻息肉的慢性鼻窦炎患者中,粘液和血清生物标记物取样的比较

研究人员分析了粘液和血清在生物标志物分析中的优缺点。血清和粘液都是 "液体活检 "的可行介质,粘液SerpinF2是预测早期复发的最佳生物标记物。